Cardiovascular risks in relation to daidzein metabolizing phenotypes among Chinese postmenopausal women

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Liu, Zhao Min ^a   Ho, Suzanne C ^a   Chen, Yu Ming ^b   Liu, Jun ^b   Woo, Jean ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DAIDZEIN; DRUG METABOLITE; EQUOL; FATTY ACID; GLUCOSE; LIPID; O DESMETHYLANGOLENSIN; UNCLASSIFIED DRUG; URIC ACID; ISOFLAVONE DERIVATIVE; O-DESMETHYLANGOLENSIN;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY COMPOSITION; BODY FAT; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; FEMALE; FOOD INTAKE; HUMAN; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE; URINALYSIS; AGED; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHEMISTRY; CHINA; CROSS-SECTIONAL STUDY; DRUG EFFECTS; LIFESTYLE; METABOLISM; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINE;

AGED; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; CHINA; CROSS-SECTIONAL STUDIES; EQUOL; FEMALE; HUMANS; ISOFLAVONES; LIFE STYLE; MIDDLE AGED; PHENOTYPE; POSTMENOPAUSE; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84895772687     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087861     Document Type: Article

References (45)

1. Ho SC, Chan AS, Ho YP, So EK, Sham A, et al. (2007) Effects of soy isoflavone supplementation on cognitive function in Chinese postmenopausal women: a double-blind, randomized, controlled trial. Menopause 14: 489-499.
2. Zhang X, Shu XO, Li H, Yang G, Li Q, et al. (2005) Prospective cohort study of soy food consumption and risk of bone fracture among postmenopausal women. Arch Intern Med 165: 1890-1895. (Pubitemid 41352084)
3. Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, et al. (2007) Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 116: 2553-2562. (Pubitemid 350179220)
4. Choi HK, Liu S, Curhan G (2005) Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: The third national health and nutrition examination survey. Arthritis and Rheumatism 52: 283-289. (Pubitemid 40129260)
5. Cano A, Garcia-Perez MA, Tarin JJ (2010) Isoflavones and cardiovascular disease. Maturitas 67: 219-226.
6. Beavers KM, Jonnalagadda SS, Messina MJ (2009) Soy consumption, adhesion molecules, and pro-inflammatory cytokines: a brief review of the literature. Nutr Rev 67: 213-221.
7. Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132: 3577-3584. (Pubitemid 35435031)
8. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, et al. (2004) Comparisons of percent equol producers between prostate vancer patients and controls: Case-controlled studies of isoflavones in Japanese, Korean and American residents. Japanese Journal of Clinical Oncology 34: 86-89. (Pubitemid 43115325)
9. Jackson RL, Greiwe JS, Schwen RJ (2011) Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutr Rev 69: 432-448.
10. Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132: 3577-3584. (Pubitemid 35435031)
11. Frankenfeld CL (2011) O-desmethylangolensin: the importance of equol's lesser known cousin to human health. Adv Nutr 2: 317-324.
12. Lampe JW (2009) Is equol the key to the efficacy of soy foods? Am J Clin Nutr 89: 1664S-1667S.
13. Guo K, Zhang B, Chen C, Uchiyama S, Ueno T, et al. (2010) Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China. Br J Nutr 104: 118-124.
14. Liu B, Qin L, Liu A, Uchiyama S, Ueno T, et al. (2010) Prevalence of the equol-producer phenotype and its relationship with dietary isoflavone and serum lipids in healthy Chinese adults. J Epidemiol 20: 377-384.
15. Setchell KDR, Cole SJ (2006) Method of Defining Equol-Producer Status and Its Frequency among Vegetarians. 2188-2193.
16. Frankenfeld CL, Atkinson C, Thomas WK, Goode EL, Gonzalez A, et al. (2004) Familial correlations, segregation analysis, and nongenetic correlates of soy isoflavone-metabolizing phenotypes. Exp Biol Med (Maywood) 229: 902-913. (Pubitemid 39539375)
17. Liu Z-m, Ho SC, Chen Y-m, Woo J (2013) A Six-Month Randomized Controlled Trial of Whole Soy and Isoflavones Daidzein on Body Composition in Equol-Producing Postmenopausal Women with Prehypertension. Journal of Obesity 2013: 9.
18. Ma J, Liu Z, Ling W (2003) Physical activity, diet and cardiovascular disease risks in Chinese women. Public Health Nutr 6: 139-146. (Pubitemid 36542430)
19. Zhang CX, Ho SC (2009) Validity and reproducibility of a food frequency Questionnaire among Chinese women in Guangdong province. Asia Pac J Clin Nutr 18: 240-250.
20. Yue-xin Y (2002) China Food Composition 2002. Institute of Nutrition and Food Safety. Beijing, PR China Peking University Medical Press.
21. Seo A, Morr CV (1984) Improved high-performance liquid chromatographic analysis of phenolic acids and isoflavonoids from soybean protein products. Journal of Agricultural and Food Chemistry 32: 530-533.
22. Arai Y, Uehara M, Sato Y, Kimira M, Eboshida A, et al. (2000) Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 10: 127-135.
23. Guo K, Zhang B, Chen C, Uchiyama S, Ueno T, et al. (2010) Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China. British Journal of Nutrition 104: 118-124.
24. Song KB, Atkinson C, Frankenfeld CL, Jokela T, Wahala K, et al. (2006) Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr 136: 1347-1351.
25. Decroos K, Vanhemmens S, Cattoir S, Boon N, Verstraete W (2005) Isolation and characterisation of an equol-producing mixed microbial culture from a human faecal sample and its activity under gastrointestinal conditions. Arch Microbiol 183: 45-55. (Pubitemid 40142881)
26. Mai V (2004) Dietary modification of the intestinal microbiota. Nutr Rev 62: 235-242.
27. Gardana C, Canzi E, Simonetti P (2009) The role of diet in the metabolism of daidzein by human faecal microbiota sampled from Italian volunteers. J Nutr Biochem 20: 940-947.
28. Bolca S, Possemiers S, Herregat A, Huybrechts I, Heyerick A, et al. (2007) Microbial and dietary factors are associated with the equol producer phenotype in healthy postmenopausal women. J Nutr 137: 2242-2246. (Pubitemid 47529584)
29. Atkinson C, Newton KM, Bowles EJ, Yong M, Lampe JW (2008) Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. Am J Clin Nutr 87: 679-687. (Pubitemid 351364550)
30. Lampe JW, Skor HE, Li S, Wahala K, Howald WN, et al. (2001) Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 131: 740-744. (Pubitemid 32199139)
31. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, et al. (2005) Association of serum phytoestrogen concentration and dietary habits in a sample set of the JACC Study. J Epidemiol 15 Suppl 2: S196-202. (Pubitemid 41410104)
32. Vedrine N, Mathey J, Morand C, Brandolini M, Davicco MJ, et al. (2006) One-month exposure to soy isoflavones did not induce the ability to produce equol in postmenopausal women. Eur J Clin Nutr 60: 1039-1045. (Pubitemid 44340401)
33. Hedlund TE, Maroni PD, Ferucci PG, Dayton R, Barnes S, et al. (2005) Longterm dietary habits affect soy isoflavone metabolism and accumulation in prostatic fluid in caucasian men. J Nutr 135: 1400-1406. (Pubitemid 40799602)
34. Atkinson C, Newton KM, Yong M, Stanczyk FZ, Westerlind KC, et al. (2012) Daidzein-metabolizing phenotypes in relation to bone density and body composition among premenopausal women in the United States. Metabolism 61: 1678-1682.
35. Cordain L, Latin RW, Behnke JJ (1986) The effects of an aerobic running program on bowel transit time. J Sports Med Phys Fitness 26: 101-104. (Pubitemid 16080366)
36. Koffler KH, Menkes A, Redmond RA, Whitehead WE, Pratley RE, et al. (1992) Strength training accelerates gastrointestinal transit in middle-aged and older men. Med Sci Sports Exerc 24: 415-419.
37. Child MW, Kennedy A, Walker AW, Bahrami B, Macfarlane S, et al. (2006) Studies on the effect of system retention time on bacterial populations colonizing a three-stage continuous culture model of the human large gut using FISH techniques. FEMS Microbiol Ecol 55: 299-310.
38. Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF (2005) Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J Nutr Biochem 16: 321-330. (Pubitemid 40776040)
39. Hwang J, Wang J, Morazzoni P, Hodis HN, Sevanian A (2003) The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic Biol Med 34: 1271-1282. (Pubitemid 36513970)
40. Adlercreutz H, Martin F, Pulkkinen M, Dencker H, Rimér U, et al. (1976) Intestinal metabolism of estrogens. Journal of Clinical Endocrinology and Metabolism 43: 497-505.
41. Boden G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18: 139-143.
42. Population Health Survey 2003/2004. Hong Kong: Department of Health. 1-315.
43. Janus ED, Watt NM, Lam KS, Cockram CS, Siu ST, et al. (2000) The prevalence of diabetes, association with cardiovascular risk factors and implications of diagnostic criteria (ADA 1997 and WHO 1998) in a 1996 community-based population study in Hong Kong Chinese. Hong Kong Cardiovascular Risk Factor Steering Committee. American Diabetes Association. Diabet Med 17: 741-745.
44. Protection CfH (2013) Hypertension.
45. Atkinson C, Newton KM, Aiello Bowles EJ, Lehman CD, Stanczyk FZ, et al. (2009) Daidzein-metabolizing phenotypes in relation to mammographic breast density among premenopausal women in the United States. Breast Cancer Res Treat 116: 587-594.